Beta Thalassemia Treatment Industry- Regional Synopsis
North America Market Forecasts
The beta thalassemia treatment market in the North America is set to hold the largest revenue share of 33% during the assessment period. The growth of the market in this region can be attributed on the account of several factors such as the increasing presence of market players in the region, and the growing research and development activities taking place for the approval and development of new technologies in beta thalassemia treatment. Bluebird Bio, a biotech company from the U.S. declared on September 21, 2021, that it had filed a formal application for approval of beticel gene therapy to treat beta-thalassemia within the United States.
APAC Market Statistics
The beta-thalassemia treatment market in the Asia Pacific region is poised to grow substantially by the end of 2037. The growth of this market can be attributed to the back of increasing investment in the healthcare infrastructure of the region, the large population patient pool, availability of massive untapped markets in the region. Besides, increasing demand for quality healthcare facilities in this region is also estimated to boost the market growth in this region in the upcoming time period.
